top of page

Australia TGA: eCTD AU module 1 and regional information

Writer: Sharan MuruganSharan Murugan

Australia's Therapeutic Goods Administration (TGA) released updated guidance "eCTD AU module 1 and regional information" on 30 January 2024, which provides Specifications and guidance for use, V3.1 to compile an eCTD dossier for Australia.


This guidance applies to all regulatory activities in electronic Common Technical Document (eCTD) format and the document replaces AU eCTD specification - Module 1 and regional information Version 3.0 and contains updated information.


The reason behind the update is to provide support for the implementation of the Medicines and Medical Device Review (MMDR) recommendations, including priority, provisions, and notification pathways, as well as the possibility of multiple change requests being submitted in one eCTD dossier.


The other reasons include providing greater clarity to users, enhancing dossier quality, and allowing for automation of some process steps within the TGA.


The document contains:

  • guidance for compiling an eCTD dossier

  • specifications for compiling and validating your eCTD regulatory activity.


As part of the upgrade to version 3.1, the following documents and specifications have been updated:


The Module-1 v3.1 of the specification is being reformed and the milestones and updates can be found on the Module-1 v3.2 implementation plan.

Comentarios


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page